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ABSTRACT
Genetic and environmental determinants of skeletal phenotypes such as bone mineral density (BMD) may converge through the
epigenome, providing a tool to better understand osteoporosis pathophysiology. Because the epigenetics of BMD have been largely
unexplored in humans, we performed an epigenome-wide association study (EWAS) of BMD. We undertook a large-scale BMD EWAS
using the InﬁniumHumanMethylation450 array tomeasure site-speciﬁc DNAmethylation in up to 5515 European-descent individuals
(NDiscovery¼ 4614,NValidation¼ 901).We associatedmethylation atmultiple cytosine-phosphate-guanine (CpG) siteswith dual-energy X-
ray absorptiometry (DXA)-derived femoral neck and lumbar spine BMD. We performed sex-combined and stratiﬁed analyses,
controlling for age, weight, smoking status, estimated white blood cell proportions, and random effects for relatedness and batch
effects. A 5% false-discovery ratewas used to identify CpGs associatedwith BMD.We identiﬁed one CpG site, cg23196985, signiﬁcantly
associatedwith femoral neck BMD in 3232 females (p¼ 7.9 1011) and4614 females andmales (p¼ 3.0 108). cg23196985was not
associated with femoral neck BMD in an additional sample of 474 females (p¼ 0.64) and 901 males and females (p¼ 0.60). Lack of
strong consistent association signal indicates that among the tested probes, no large-effect epigenetic changes in whole blood
associated with BMD, suggesting future epigenomic studies of musculoskeletal traits measure DNA methylation in a different tissue
with extended genome coverage. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Osteoporosis is primarily an aging-related disease character-ized by compromised bone strength that increases the risk
of fracture. Because of population aging worldwide, the
incidence of osteoporosis is increasing, exceeding $17 billion
per year in direct care costs within the United States(1) and
costing upward of s37 billion per year in the EU-27 member
states.(2) Identifying the causes of osteoporosis will improve the
understanding of its pathology, leading to better or more
efﬁcient treatments of this common and costly disease. Low
bone mineral density (BMD) is one of the major risk factors for
fracture and is largely used in clinical prediction tools for fracture
and gauging response to treatment. Genome-wide association
studies (GWAS) of BMDdirectly assessed at the femoral neck (FN)
and lumbar spine (LS), the two most commonly measured sites
for quantifying BMD and diagnosing osteoporosis, have been
instrumental in identifying novel genetic loci inﬂuencing
osteoporosis disease risk.(3,4) However, epigenetic variation in
the genome, which can be inﬂuenced by both genetic and
environmental factors,(5,6) may also inﬂuence BMD, yet the
epigenetic inﬂuences on BMD have largely been unexplored.
One of the most stable epigenetic processes is DNA
methylation, or the addition of a CH3 methyl group to cytosine,
typically in the context of cytosine paired sequentially to a
guanine nucleotide, separated by a phosphate group (CpG).
DNAmethylation is known to play a role in gene expression and
cell differentiation,(7,8) and differential DNA methylation has
been linked to multiple human complex traits and disease
phenotypes.(5,9–12) Studies performed using bone samples have
identiﬁed epigenetic alterations that inﬂuence bone cell
function.(13,14) We studied epigenetic variation in whole blood,
as a proxy for difﬁcult-to-acquire samples such as bone, in
relation to BMD because epigenetic markers are often stable
across multiple tissues, and immune cells within blood are
known to inﬂuence bone homeostasis.(15) Furthermore, osteo-
clasts are derived from the monocyte-macrophage lineage
found in whole blood.(16) Although epigenetic proﬁling has
been performed previously in bone samples from osteoporotic
and osteoarthritic patients(17) and an epigenome-wide associa-
tion study (EWAS) of BMD has been performed in mice,(18) EWAS
of BMD have not been reported in humans with validation of
signiﬁcant ﬁndings.
We, therefore, undertook a large-scale BMD EWAS, assessing
the association of up to 473,882 CpGs quantiﬁed in whole blood
with BMDmeasured in up to 4614 individuals across ﬁve cohorts
from Europe and North America. To our knowledge, this study is
the largest EWAS of a musculoskeletal trait performed to date.
We used an additional 901 individuals as a validation cohort to
increase the reliability of our results.
Materials and Methods
Individual cohorts
We performed our EWAS in cohorts composed of European-
descent individuals. Cohorts used for the discovery analysis were
the TwinsUK Registry (TUK), FraminghamStudyOffspring Cohort
(FOS), Avon Longitudinal Study of Parents and Children
(ALSPAC; further information on the ALSPAC cohorts and ARIES
project is included in Supplemental Table S1), Rotterdam Study
(RS), and the Danish Twin Registry (DTR). The cohort used for
validation of signiﬁcant ﬁndings was the Framingham Study
Generation 3 cohort (Gen3), a cohort including family members
of FOS (Table 1; Supplemental Table S1).
Both, or one of, FN and LS BMDwere measured in each cohort
by dual-energy X-ray absorptiometry (DXA) (Supplemental
Table S2). All cohorts, except the ALSPAC and DTR, followed
the same methods for extracting DNA from whole-blood tissue
and quantifying DNAmethylation. Whole-blood tissue DNA was
extracted using the DNeasy Blood & Tissue Kit (Qiagen, Inc.,
Valencia, CA, USA), followed by bisulﬁte conversion of 750 ng
DNA using the EZ DNA Methylation Kit (Zymo Research, Irvine,
CA, USA) following manufacturer instructions. The ALSPAC
cohort and the DTR cohort performed DNA extraction and
conversion as described previously.(19,20) DNA methylation
across the genome was quantiﬁed using the Inﬁnium Human-
Methylation450 BeadChip (Illumina, San Diego, CA, USA),
assaying up to 482,421 CpGs throughout the human genome.
Image intensities were extracted using GenomeStudio Methyl-
ation Module (v1.8) software. Cohort-speciﬁc criteria were
applied in further quality control and normalization of probe
intensities (Supplemental Table S3).
Statistical analyses
For discovery analyses, each cohort followed a prespeciﬁed
analysis plan. FN and LS BMD residuals were calculated by ﬁtting
a linear regression model, adjusting for age, weight, and sex. For
sex-speciﬁc analyses, the term for sex was removed from the
model. In addition, the DTR adjusted for birth weight
discordance as historically DTR samples were selected to
address birth weight discordance in twins (Supplemental
Table S1). To address the issue of cell heterogeneity in whole
blood tissue, each cohort calculated the estimated white blood
cell proportions of B cells, T cells (CD4þ and CD8þ),
granulocytes, natural killer cells, and monocytes using the
Houseman and colleagues method for quadratic projections.(21)
DNA methylation for each probe was transformed to a standard
normal distribution using quantile normalization. The associa-
tion between DNAmethylation and BMDwas then calculated by
ﬁtting a linear mixed effects model for normalized DNA
methylation, including BMD residuals, smoking (measured as
smokers, non-smokers, or former smokers), age, weight, sex, and
estimated white blood cell proportions as ﬁxed effects, and
terms for family structure and batch effects as random effects,
where relevant. We used BMD residuals to reduce problems due
to collinearity between BMD, weight, and age when ﬁtting our
linear mixed-effects model. Association testing was performed
in male, female, and combined samples. Each cohort was
assessed for epigenome-wide statistical inﬂation by calculating
the genomic inﬂation factor lambda (l) and generating a
quantile-quantile plot (QQ-plot). Lambda can be calculated to
estimate the deviation of a distribution from a null expected
distribution, whereas QQ plots can be used to visualize the
deviation of a distribution from a null expected distribution.
Fixed-effects meta-analyses were performed using METAL(22)
for FN and LS sex-combined and sex-stratiﬁed analyses. We used
the I2 statistic to quantify the variability in association effect
estimates due to statistical heterogeneity, excluding probes
with heterogeneous I2 statistics (pHet< 0.05). Statistical signiﬁ-
cance, when considering the multiple testing burden, was
determined by calculating Benjamini-Hochberg (BH) adjusted p
values for each meta-analysis. Probes with signiﬁcant BH-
adjusted p values (pBH< 0.05) would, therefore, be signiﬁcant at
a 5% false-discovery rate (FDR). Summary statistics for the FN
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and LS sex-combined and sex-stratiﬁed meta-analyses are
available for download (www.gefos.org).
Associated probes were assessed for their twin-based
heritability using normalized methylation beta values estimated
from 330 female MZ twin pairs and 34 female DZ twin pairs from
the TUK cohort, adjusted for age, body mass index, smoking
status, alcohol consumption, predicted whole blood cell-type
counts, DNA methylation plate, and position on the plate.
Heritability was estimated by ﬁtting the classical ACE model in
OpenMX.(23) The observed variance in the adjusted beta values
was partitioned into additive genetic (A), common environmen-
tal (C), and unique environmental (E) factors. Heritability was
deﬁned as A/(AþCþE).
Associated probes were assessed for the inﬂuence of single
nucleotide polymorphisms (SNPs) that overlapped the probe
body by mapping these probes to dbSNP 146.(24) This was
assessed by adding a term for the dosage of each SNP to the
discovery linear mixed-effects models in cohorts with genotype
data to observe if the association betweenDNAmethylation and
BMD was inﬂuenced by the genetic polymorphism at the probe.
Gen3 samples were assessed using the same methods as in
the analysis of FOS samples to perform validation analyses of
signiﬁcantly associated probes. Probes were deemed robustly
associated with BMD if they met a validation p value of less than
0.05. These samples are not completely independent from the
FOS samples because the Framingham Study is a family-based
study with several cohorts, and, therefore, there is underlying
family structure.
To assess the power of our study, we performed 5000
permutations on the 775 TUK samples with FN BMD measure-
ments. FN was randomly sampled based on the twin and family
structure before ﬁtting linear mixed-effects models, and the
power was deﬁned as the number of permutations with p values
greater than the observed p value for the TUK samples
(p¼ 1.14 105; Supplemental Table S8).
Results
Meta-analysis
Meta-analyses of discovery cohorts identiﬁed CpG site
cg23196985 associated at a 5% FDR for FN sex-combined
(b¼ 0.66, SE¼ 0.19, p¼ 2.99 108, pBH¼ 1.30 10
2) and FN
female (b¼ 0.95, SE¼ 0.15, p¼ 7.86 1011, pBH¼ 3.41 10
5;
Fig. 1, Fig. 2, Table 2) analyses. CpG site cg23196985maps to the
5’ untranslated region of the liver carboxylase 1 gene (CES1),
which is expressed in the liver and whole blood(25) yet with no
currently reported associations with BMD by GWAS in the same
chromosomal region (16q12.2) and with the nearest BMD-
associated SNP mapping approximately 4 mega base pairs
upstream at the SALL1 and CYLD locus.(26) The calculated
lambdas and QQ plots for the meta-analyses of FN female and
sex-combined analyses revealed no statistical inﬂation of the
association p values (lfemale¼ 1.02, lsex-combined¼ 0.97; Supple-
mental Table S9). We observed no signiﬁcantly associated CpG
sites with LS BMD in sex-combined or sex-stratiﬁed analyses
(Supplemental Figures).
We tested for the inﬂuence of SNPs underlying cg23196985 in
females from the FOS, RS, and ALSPAC cohorts, as the strength of
the association was stronger in females than in the sex-
combined analysis. Because some of the samples in our cohorts
included twins, we ﬁrst estimated the evidence for heritability of
DNA methylation levels at cg23196985 in the TUK cohort. We
observed evidence for additive genetic effects with a heritability
estimate of 0.69 at cg23196985 and therefore pursued further
analyses exploring the association between DNA methylation
levels at this CpG site and BMD conditional on SNP genotypes.
All twins were homozygous for the reference allele at
rs144950224, a SNP that maps directly to the probe’s target
CpG site. Four SNPs mapped to the cg23196985 50 base-pair
probe sequence, and these included rs144950224, rs12149371,
rs12149373, and rs3815583. SNP rs144950224 was found to be
rare within our cohorts, with a minor allele frequency (MAF) of
approximately 0.5% in FOS samples, 0.1% in RS samples, and no
carriers in ALSPAC samples. We observed no notable change in
association p values upon conditioning with each of the four
SNPs (Supplemental Table S10).
In the validation sample, cg23196985 was not associated
with FN in Gen3 female (p¼ 0.64) and sex-combined (p¼ 0.60)
analyses. However, after meta-analyzing Gen3 validation data
with discovery results, the probe remained strongly associated
in female-only analyses (b¼ 0.86, SE¼ 0.14, p¼ 3.7 1010;
n¼ 4345) but not in sex-combined analysis (p¼ 0.68,
n¼ 5301).
For our power calculation, we found all permutations were
less signiﬁcant than our observed p value for the 775 TUK
samples at p¼ 1.14 105 (permuted p value range 0.99 to
2.46 105); this suggested we had 100% power to detect the
observed effect size (b¼ 1.20, SE¼ 0.27) between bone density
measurements and methylation at cg23196985 in CES1.
Table 1. Sample Sizes of Discovery and Replication Cohorts
Sample size
FN BMD LS BMD
Phase Cohort Pooled Females Males Pooled Females Males
Avon Longitudinal Study of Parents and Children (ALSPAC) 715 715 0 0 0 0
Danish Twin Registry (DTR) 267 132 135 260 132 128
Discovery Framingham Study Offspring Cohort (FOS) 2207 1254 953 2203 1259 953
Rotterdam Study (RS) 650 356 294 633 346 287
TwinsUK (TUK) 775 775 0 770 770 0
Discovery total 4614 3232 1382 3866 2507 1368
Validation FOS Gen3 901 448 453 0 0 0
Discoveryþ Validation total 5515 3680 1835 3866 2507 1368
FN¼ femoral neck; BMD¼bone mineral density; LS¼ lumbar spine.
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Individual cohorts
Individual cohort analyses identiﬁed seven probes that were
signiﬁcantly associated in two cohorts with sex-combined or
sex-stratiﬁed analyses (Supplemental Table S4), but there were
no other cohort-speciﬁc signiﬁcant associations. The DTR LS
female analysis identiﬁed four signiﬁcantly associated probes,
two of whichmap to genes, cg04081651 (MAP3K8), cg09832237,
cg14793931 (ZFR2), and cg24029028 (Supplemental Table S5).
The DTR LS male analysis identiﬁed one signiﬁcantly associated
probe, cg23214071 (HLA-DQB1) (Supplemental Table S6).
The TUK LS female analysis identiﬁed two signiﬁcantly
associated probes, cg24117468 (P4HA2) and cg02526790 (TG)
(Supplemental Table S7). The calculated lambda and QQ plot for
the DTR LS female analysis revealed statistical inﬂation of
the association p values (l¼ 1.46), but the lambda and QQ plots
for the remainder of the cohorts showed no large inﬂation or
deﬂation of association p values (Supplemental Table S9).
Discussion
In the ﬁrst large-scale assessment of the contribution of
epigenetic changes in whole blood to BMD, we did not identify
methylation changes reliably associated with this clinically
relevant trait. CpG site cg23196985 was found in the discovery
meta-analysis to be strongly associated with FN BMD in females
only and in analyses combining males and females, but upon
validation in an extended sample that included related
individuals, the association was attenuated in the female
analysis and completely absent in sex-combined analyses.
These ﬁndings provide important insights into the ﬁeld of
epigenetics. The ﬁrst is that by using a precisely measured trait,
BMD, which is highly heritable with estimates from 50% to
85%(27) and for which genetic determinants have been identiﬁed
through GWAS,(3,4,27) there do not appear to be associations
between methylation changes and BMD. Although whole blood
methylation changesmay not be the ideal tissuewithin which to
test epigenetic inﬂuences on bone, this conveniently accessible
tissue has many links to bone biology, including the fact that
osteoclasts and monocyte/macrophages originate from the
same precursors.(15,16) The extent to which methylation changes
are shared between bone and whole blood is not well known.
However, evidence shows that a signiﬁcant proportion of
methylation variation genome-wide can be conserved across
tissues.(28) Additional explanations for our mostly null ﬁndings
include the possibility that DNA methylation changes may not
have a large inﬂuence on BMD.
Notwithstanding the general lack of consistent associations
with BMD across the genome, we did generate evidence for
suggestive association of cg23196985 with FN BMD in females.
However, we caution that these ﬁndings require further
replication. Because we are unaware of any available replication
data to test this hypothesis, these ﬁndings will require
replication in future studies.
There is limited evidence for the effects of DNA methylation
on bone. A methylation proﬁling study that compared the
differences between bone samples of 27 osteoporotic and 23
osteoarthritic patients was undertaken on an earlier DNA
methylation platform, the HumanMethylation27 BeadChip
(assessing approximately 27,000 CpGs in the genome), and
was able to identify bone genes following pathway analyses of
more than 200 differentially methylated CpGs; however, to date,
these results lack replication.(17) Another study failed to
demonstrate speciﬁc effects of DNA methylation, assessed by
sequencing methods, on RANKL in the bones of patients with
osteoporotic fractures.(29) The evidence from previous studies
and our own suggests that if strong effects of DNA methylation
on bone biology are to be identiﬁed, theymay not be detectable
with current analytical approaches.
A strength of our studywas the sample size and a conservative
estimate of statistical power to identify epigenetic effects on
BMD that account for 0.8% of its variance. The large sample size
also allowed us to classify several cohort-level associations that
were likely to be false positives. For example, TUK female
analyses identiﬁed two probes signiﬁcantly associated with LS
Fig. 1. Quantile-quantile plots (QQ plots) of the distribution of observed
log10 association p values against the expected null distribution, for
discovery meta-analyses of FN BMD in (A) females-only and (B) sex-
combined analyses. Genomic inﬂation lambda scores are given in each
QQ plot to quantify statistical inﬂation of p values. No evidence for
inﬂationwas observed in the QQ plots or as calculated by lambda scores.
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BMD, but this association was not observed in any other cohort,
suggesting the associations were false positives (Supplemental
Tables S4 and S5).
One of the key limitations of cohort-based epigenetic studies
is the lack of cell-sorted data for analysis. As discussed by Birney
and colleagues,(30) optimal planning at the outset of a study is
ideal; however, such coordination is difﬁcult to implement in
large cohorts and so bioinformatics methods must be applied
post hoc to adjust for suboptimal study designs. We adjusted for
cell heterogeneity within whole blood, and therefore the signal
we tested for association with BMD would be ubiquitous within
whole blood. Such ubiquitous signals within whole blood may
only be detectable for extremely strong environmental
modiﬁers of DNA methylation, such as cigarette smoking.(5,6)
Fig. 2. Manhattan plots of log10 association p values for discovery meta-analyses of FN BMD in (A) females-only and (B) sex-combined analyses.
Table 2.Meta-Analysis Results for Association of cg23196985with FN BMD in Both Female and Sex-Pooled Analyses in Discovery phase,
with Replication and Combined Discovery and Replication Analyses
Discovery Validation Combined
b SE p pBH pHet b SE p b SE p pHet
Female 0.95 0.15 7.9E-11 3.4E-05 0.81 0.19 0.39 0.64 0.86 0.14 3.8E-10 0.43
Sex pooled 0.66 0.12 3.0E-08 1.3E-02 0.1 –0.01 0.02 0.6 0.01 0.02 0.68 3.0E-07
FN¼ femoral neck; BMD¼bonemineral density; b¼ effect size; SE¼ standard error; pBH¼ Benjamini-Hochberg adjusted p value; pHet¼heterogeneity
p value.
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Targeted EWAS of speciﬁc cell types within whole blood with
clear roles in bone biology, such as monocytes due to their
role in osteoclastogenesis, may be more fruitful. Furthermore,
longitudinal studies can identify disease-risk biomarkers and
provide mechanistic insights; however, these are generally
underpowered when studying BMD because of the relatively
small changes in BMD that occur over time. As we have shown
that large-scale whole blood EWAS of BMD does not identify
disease-risk biomarkers for osteoporosis risk, a well-powered
longitudinal study with a wide range of time points and bone
samples may be more informative.
In the largest EWAS meta-analysis to date of BMD, we
observed a probe near CES1 to be associated with FN BMD in the
discovery sample of up to 4826 individuals but not with the
same phenotype in a related validation sample of 901
individuals. In conclusion, these ﬁndings suggest that there
are no large effects of methylation changes on BMD in whole
blood in the epigenome, which are common and well captured
by the Inﬁnium HumanMethylation450 BeadChip.
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